Search
                    Cyclophosphamide Treatment Options in Fort Worth, TX
A collection of 129 research studies where Cyclophosphamide is the interventional treatment. These studies are located in the Fort Worth, TX. Cyclophosphamide is used for conditions such as Breast Cancer, Lymphoma and Leukemia.
            49 - 60 of 129
        Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    
                
                                    Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients
                                
            
            
        Active Not Recruiting
                            
            
                This is a phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to compare the efficacy and safety of the humanized monoclonal anti CD19 antibody tafasitamab plus lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) versus R-CHOP in previously untreated, high-intermediate and high-risk patients with newly-diagnosed DLBCL             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 80 years
            Trial Updated:
                08/06/2024
            
            Locations: MorphoSys Research Site, Austin, Texas  +6 locations         
        
        
            Conditions: Diffuse Large B-cell Lymphoma
        
            
        
    
                
                                    Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
                                
            
            
        Completed
                            
            
                This pilot clinical trial studies busulfan, melphalan, and stem cell transplant after chemotherapy in treating patients with newly diagnosed neuroblastoma that is likely to come back or spread. Giving chemotherapy to the entire body before a stem cell transplant stops the growth of tumor cells by stopping them from dividing or killing them. After treatment, stem cells are collected from the patient's blood and stored. More chemotherapy or radiation therapy is given to prepare the bone marrow for...  Read More             
        
        
    Gender:
                ALL
            Ages:
                30 years and below
            Trial Updated:
                07/03/2024
            
            Locations: UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas  +4 locations         
        
        
            Conditions: Stage 4S Neuroblastoma, Ganglioneuroblastoma, Stage 1 Neuroblastoma, Stage 2 Neuroblastoma, Stage 2A Neuroblastoma, Stage 2B Neuroblastoma, Stage 3 Neuroblastoma, Stage 4 Neuroblastoma
        
            
        
    
                
                                    Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia
                                
            
            
        Completed
                            
            
                This phase III trial studies combination chemotherapy with or without lestaurtinib with to see how well they work in treating younger patients with newly diagnosed acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of stop cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Lestaurtinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. It is not yet...  Read More             
        
        
    Gender:
                ALL
            Ages:
                1 year and below
            Trial Updated:
                07/03/2024
            
            Locations: Texas Tech University Health Sciences Center-Amarillo, Amarillo, Texas  +10 locations         
        
        
            Conditions: Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Childhood T Acute Lymphoblastic Leukemia
        
            
        
    
                
                                    Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer
                                
            
            
        Active Not Recruiting
                            
            
                This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whethe...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                05/31/2024
            
            Locations: Hendrick Medical Center, Abilene, Texas  +47 locations         
        
        
            Conditions: Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative, Progesterone Receptor Negative, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Carcinoma
        
            
        
    
                
                                    Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma
                                
            
            
        Completed
                            
            
                This partially randomized phase II trial studies how well brentuximab vedotin or crizotinib and combination chemotherapy works in treating patients with newly diagnosed stage II-IV anaplastic large cell lymphoma. Brentuximab vedotin is a monoclonal antibody, called brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in targeted way and delivers vedotin to kill them. Crizotinib and methotrexate may stop the growth of cancer cells by blocking som...  Read More             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                04/04/2024
            
            Locations: Dell Children's Medical Center of Central Texas, Austin, Texas  +10 locations         
        
        
            Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
        
            
        
    
                
                                    Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System
                                
            
            
        Completed
                            
            
                This phase III trial studies the side effects of combination chemotherapy, 3-dimensional conformal radiation therapy, and an autologous peripheral blood stem cell transplant, and to see how well they work in treating young patients with atypical teratoid/rhabdoid tumor of the central nervous system. Giving high-dose chemotherapy before an autologous peripheral blood stem cell transplant stops the growth of cancer cells by stopping them from dividing or killing them. Giving colony-stimulating fac...  Read More             
        
        
    Gender:
                ALL
            Ages:
                21 years and below
            Trial Updated:
                04/03/2024
            
            Locations: Driscoll Children's Hospital, Corpus Christi, Texas  +4 locations         
        
        
            Conditions: Childhood Atypical Teratoid/Rhabdoid Tumor
        
            
        
    
                
                                    Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia
                                
            
            
        Completed
                            
            
                This randomized phase III trial is studying low-dose vincristine to see how well it works compared with high-dose vincristine when given together with different combination chemotherapy regimens in treating young patients with intermediate-risk relapsed B-cell acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) and giv...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 29 years
            Trial Updated:
                03/04/2024
            
            Locations: Texas Tech University Health Science Center-Amarillo, Amarillo, Texas  +11 locations         
        
        
            Conditions: B-cell Childhood Acute Lymphoblastic Leukemia, L1 Childhood Acute Lymphoblastic Leukemia, L2 Childhood Acute Lymphoblastic Leukemia, Intermediate Risk Recurrent Childhood Acute Lymphoblastic Leukemia
        
            
        
    
                
                                    A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer
                                
            
            
        Completed
                            
            
                This is a global Phase III, double-blind, randomized, placebo-controlled study designed to evaluate the efficacy and safety of neoadjuvant treatment with atezolizumab (anti-programmed death-ligand 1 \[anti-PD-L1\] antibody) and nab-paclitaxel followed by doxorubicin and cyclophosphamide (nab-pac-AC), or placebo and nab-pac-AC in participants eligible for surgery with initial clinically assessed triple-negative breast cancer (TNBC).             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                10/23/2023
            
            Locations: The Center for Cancer and Blood Disorders - Fort Worth, Fort Worth, Texas         
        
        
            Conditions: Triple-negative Breast Cancer
        
            
        
    
                
                                    Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which chemotherapy regimen combined with radiation therapy and/or surgery is more effective in treating Ewing's sarcoma or primitive neuroectodermal tumor.
PURPOSE: Randomized phase III trial to compare the effectiveness of different chemotherapy regimens combined with radiation therapy an...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 0 years and 50 years
            Trial Updated:
                08/01/2023
            
            Locations: Texas Tech University Health Sciences Center School of Medicine, Amarillo, Texas  +15 locations         
        
        
            Conditions: Sarcoma
        
            
        
    
                
                                    A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
                                
            
            
        Completed
                            
            
                This is a phase I study of temsirolimus (Torisel) combined with dexamethasone, cyclophosphamide and etoposide in patients with relapsed acute lymphoblastic leukemia (ALL), lymphoblastic lymphoma (LL) or peripheral T-cell lymphoma (PTL).             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 21 years
            Trial Updated:
                07/25/2023
            
            Locations: University of Texas at Southwestern, Dallas, Texas  +2 locations         
        
        
            Conditions: Lymphoblastic Leukemia, Acute, Childhood, Lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
        
            
        
    
                
                                    N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma
                                
            
            
        Completed
                            
            
                RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Zoledronic acid may stop the growth of tumor cells in bone. Giving bevacizumab toget...  Read More             
        
        
    Gender:
                ALL
            Ages:
                30 years and below
            Trial Updated:
                04/06/2023
            
            Locations: Cook Children's Medical Center - Fort Worth, Fort Worth, Texas  +1 locations         
        
        
            Conditions: Neuroblastoma
        
            
        
    
                
                                    Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
                                
            
            
        Completed
                            
            
                RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells. It is not yet known which regimen of combination chemotherapy is more effective for childhood acute lymphoblastic leukemia.
PURPOSE: This randomized phase III trial is comparing different regimens of combination chemotherapy to see how well they work in treating children with acute lymphoblastic leukemia.             
        
        
    Gender:
                ALL
            Ages:
                Between 1 year and 9 years
            Trial Updated:
                04/04/2023
            
            Locations: Driscoll Children's Hospital, Corpus Christi, Texas  +10 locations         
        
        
            Conditions: Leukemia
        
            
        
    49 - 60 of 129
            